Selective ghrelin-receptor agonist (GHRP)
Ipamorelin
Selective ghrelin-receptor agonist for clean GH release.
- Half-life~2 hours plasma
- Dose range200 to 300 mcg per administration, 1 to 3 times daily · 8 to 12 week cycle
- Reconstituted stability28 days, 2–8 °C
- VerificationCOA included
Mechanism
How it works.
Binds the GH-secretagogue receptor (GHSR-1a) at the pituitary. Triggers a clean GH pulse without cortisol, prolactin, or ACTH elevation.
Research
What the research shows.
Research base is strong on the selectivity profile. Combined with CJC-1295 (GHRH analog) for synergistic GH-pulse effect. Pre-bed dosing aligns with natural slow-wave-sleep GH pulse.
Ipamorelin is a selective ghrelin-receptor agonist (GHRP). Unlike older secretagogues, it does not stimulate cortisol, prolactin, or ACTH release. The clean profile is the defining feature.
Research-context use pairs cleanly with CJC-1295 (GHRH analog) for the standard GH-pulse stack. Solo use produces meaningful GH release but smaller magnitude than the combined stack.
Contraindications
When not to use.
Active malignancy. Diabetic ketoacidosis. Pregnancy. Pediatric use without clinical oversight.
Optimal pairings
Stacks well with.
Information is educational, derived from published research. Not medical advice. All compounds sold for research use only. Bloodwork and a clinical consultation should precede any new protocol.